JPGN Reports case series describes tirzepatide in two adolescents with MASLD

The wire

1. 01Clinicians report their experience using tirzepatide in two adolescent patients with obesity and MASLD, published as a case series in JPGN Reports.
2. 02Pediatric specialists often manage patients into young adulthood amid transition delays and workforce shortages, so familiarity with adult MASLD pharmacotherapy is increasingly relevant to their practice.
3. 03This is a two-patient case series, not a trial; semaglutide is approved for adults with MASH and F2-F3 fibrosis while dual and triple agonists remain under evaluation.

From the source

Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series

JPGN reports · 2026 Oct 12 · Perumpail BJ, Tou A, Panganiban J et al.